- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 18, 2024
Product Development
Tumor cell surface targets off the beaten path
Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors
BioCentury | Nov 30, 2023
Deals
ImmunoGen’s commitment to Elahere pays off with $10.1B AbbVie takeout
Pharma sees opportunities for label expansions as it builds pipeline, gains commercial presence in solid tumors
BioCentury | Oct 29, 2021
Discovery & Translation
Omics-based target identification in UK Biobank and COVID-19 cohorts
Plus: technologies from Harvard, Texas A&M, Disney lab and more
BioCentury | Jun 27, 2019
Company News
Conserving cash, ImmunoGen to pursue narrower indication for bruised mirvetuximab
BioCentury | Jan 18, 2019
Product Development
ImmunoGen’s milestone year
How 2019 could yield first evidence ImmunoGen’s new growth strategy is working
Items per page:
1 - 6 of 6